ArticleOxford medical case reports2025
Rectal large cell neuroendocrine carcinoma.
Article in Oxford medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rectal large cell neuroendocrine carcinoma (LCNEC) is an exceedingly rare and aggressive neoplasm with a poor prognosis and median survival of 4-16 months. Diagnosis is challenging due to the clinical overlap with classical colorectal adenocarcinoma, and accurate diagnosis is reliant on histological examination via immunohistochemistry (IHC). For the diagnosis of LCNEC, neuroendocrine markers such as Synaptophysin, CD56, chromogranin A and Ki-67 are major determinants of the disease. We present a double case report of two individuals initially assumed diagnosed as rectal adenocarcinoma who were then re-diagnosed with rectal LCNEC via post-surgical IHC. Both patients received neo-adjuvant chemotherapy yet still developed metastatic disease. This report intends to appraise the role of routine early IHC as a critical tool for diagnosis and to guide management planning. Given the rarity and volatility of rectal LCNEC, further research is desperately needed to develop tailored treatment measures and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.